TY - JOUR
T1 - Lung ultrasound findings following COVID-19 hospitalization
T2 - A prospective longitudinal cohort study
AU - Espersen, Caroline
AU - Platz, Elke
AU - Alhakak, Alia Saed
AU - Sengeløv, Morten
AU - Simonsen, Jakob Øystein
AU - Johansen, Niklas Dyrby
AU - Davidovski, Filip Søskov
AU - Christensen, Jacob
AU - Bundgaard, Henning
AU - Hassager, Christian
AU - Jabbari, Reza
AU - Carlsen, Jørn
AU - Kirk, Ole
AU - Lindholm, Matias Greve
AU - Kristiansen, Ole Peter
AU - Nielsen, Olav Wendelboe
AU - Jeschke, Klaus Nielsen
AU - Ulrik, Charlotte Suppli
AU - Sivapalan, Pradeesh
AU - Iversen, Kasper
AU - Stæhr Jensen, Jens Ulrik
AU - Schou, Morten
AU - Skaarup, Søren Helbo
AU - Højbjerg Lassen, Mats Christian
AU - Skaarup, Kristoffer Grundtvig
AU - Biering-Sørensen, Tor
N1 - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
PY - 2022/6
Y1 - 2022/6
N2 - BACKGROUND: Lung ultrasound (LUS) is a useful tool for diagnosis and monitoring in patients with active COVID-19-infection. However, less is known about the changes in LUS findings after a hospitalization for COVID-19.METHODS: In a prospective, longitudinal study in patients with COVID-19 enrolled from non-ICU hospital units, adult patients underwent 8-zone LUS and blood sampling both during the hospitalization and 2-3 months after discharge. LUS images were analyzed blinded to clinical variables and outcomes.RESULTS: A total of 71 patients with interpretable LUS at baseline and follow up (mean age 64 years, 61% male, 24% with acute respiratory distress syndrome (ARDS)) were included. The follow-up LUS was performed a median of 72 days after the initial LUS performed during hospitalization. At baseline, 87% had pathologic LUS findings in ≥1 zone (e.g. ≥3 B-lines, confluent B-lines or subpleural or lobar consolidation), whereas 30% had pathologic findings at follow-up (p < 0.001). The total number of B-lines and LUS score decreased significantly from hospitalization to follow-up (median 17 vs. 4, p < 0.001 and 4 vs. 0, p < 0.001, respectively). On the follow-up LUS, 28% of all patients had ≥3 B-lines in ≥1 zone, whereas in those with ARDS during the baseline hospitalization (n = 17), 47% had ≥3 B-lines in ≥1 zone.CONCLUSION: LUS findings improved significantly from hospitalization to follow-up 2-3 months after discharge in COVID-19 survivors. However, persistent B-lines were frequent at follow-up, especially among those who initially had ARDS. LUS seems to be a promising method to monitor COVID-19 lung changes over time.GOV ID: NCT04377035.
AB - BACKGROUND: Lung ultrasound (LUS) is a useful tool for diagnosis and monitoring in patients with active COVID-19-infection. However, less is known about the changes in LUS findings after a hospitalization for COVID-19.METHODS: In a prospective, longitudinal study in patients with COVID-19 enrolled from non-ICU hospital units, adult patients underwent 8-zone LUS and blood sampling both during the hospitalization and 2-3 months after discharge. LUS images were analyzed blinded to clinical variables and outcomes.RESULTS: A total of 71 patients with interpretable LUS at baseline and follow up (mean age 64 years, 61% male, 24% with acute respiratory distress syndrome (ARDS)) were included. The follow-up LUS was performed a median of 72 days after the initial LUS performed during hospitalization. At baseline, 87% had pathologic LUS findings in ≥1 zone (e.g. ≥3 B-lines, confluent B-lines or subpleural or lobar consolidation), whereas 30% had pathologic findings at follow-up (p < 0.001). The total number of B-lines and LUS score decreased significantly from hospitalization to follow-up (median 17 vs. 4, p < 0.001 and 4 vs. 0, p < 0.001, respectively). On the follow-up LUS, 28% of all patients had ≥3 B-lines in ≥1 zone, whereas in those with ARDS during the baseline hospitalization (n = 17), 47% had ≥3 B-lines in ≥1 zone.CONCLUSION: LUS findings improved significantly from hospitalization to follow-up 2-3 months after discharge in COVID-19 survivors. However, persistent B-lines were frequent at follow-up, especially among those who initially had ARDS. LUS seems to be a promising method to monitor COVID-19 lung changes over time.GOV ID: NCT04377035.
KW - COVID-19
KW - Longitudinal follow-up
KW - Lung ultrasound
UR - http://www.scopus.com/inward/record.url?scp=85128446784&partnerID=8YFLogxK
U2 - 10.1016/j.rmed.2022.106826
DO - 10.1016/j.rmed.2022.106826
M3 - Journal article
C2 - 35453059
SN - 0954-6111
VL - 197
SP - 1
EP - 8
JO - Respiratory medicine
JF - Respiratory medicine
M1 - 106826
ER -